Debbie Rinde-Hoffman, MD
Cardiovascular Disease · Tampa, FLNPI 1801899091
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Abiomed at 49.0% of the total. Reporting peaked in 2024 at $42,593 and has fallen 83.4% since, to $7,060 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $347.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$44K
- Cvrx, Inc.$27K
- Boehringer Ingelheim$6K
- Lexicon Pharmaceuticals, Inc.$5K
- Abbott$3K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- plus $3K from 15 others
Across 69 payments — averaging $2923.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$173K
- Abiomed$29K
- Boehringer Ingelheim International GmbH$54
- Amgen$5
What the payments were for
- Consulting fees$24,64227%
- Speaking & faculty fees$46,27551%
- Travel & lodging$6,5497%
- Food & beverage$12,77114%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 108 | $44,253 |
| Cvrx, Inc. | 43 | $26,655 |
| Boehringer Ingelheim | 11 | $5,623 |
| Lexicon Pharmaceuticals, Inc. | 3 | $5,111 |
| Abbott | 59 | $3,132 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $2,279 |
| Lilly USA, LLC | 2 | $910 |
| One Lambda, Inc. | 1 | $750 |
| Magenta Medical Inc | 2 | $459 |
| Itamar Medical Inc | 1 | $225 |
| Edwards Lifesciences | 1 | $210 |
| Pfizer | 6 | $182 |
| Medtronic(2 entities) | 3 | $180 |
| United Therapeutics Corporation | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 3 | $63 |
| AstraZeneca | 1 | $55 |
| Boston Scientific | 2 | $35 |
| Bioventrix, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $21 |
| Nuwellis, Inc. | 1 | $20 |
| Livanova USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$37,730
- Barostim Neo System$25,807
- JARDIANCE$6,385
- Inpefa$5,040
- LifeVest$2,000
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$624
- HeartMate 3 Left Ventricular Assist Device$306
- WatchPATONE$225
- CardioMEMS HF System$218
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$210
- Mitra Clip system$156
- HeartWare HVAD$151
- CARDIOMEMS$149
- Allure Quadra RF CRT Pacemaker$132
- MitraClip System$124
How this compares
$90,302 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 182 | $295,991 |
| JardianceEmpagliflozin | 196 | $277,703 |
| EliquisApixaban | 110 | $130,761 |
| FarxigaDapagliflozin Propanediol | 104 | $107,477 |
| Repatha SureclickEvolocumab | 73 | $71,435 |
| OzempicSemaglutide | 59 | $62,251 |
| Sirolimus | 81 | $40,893 |
| WegovySemaglutide | 22 | $35,828 |
| CorlanorIvabradine Hcl | 36 | $30,765 |
| MounjaroTirzepatide | 28 | $28,593 |
| XareltoRivaroxaban | 19 | $27,304 |
| Repatha PushtronexEvolocumab | 20 | $14,948 |
| Tacrolimus | 148 | $13,571 |
| Cyclosporine | 12 | $7,966 |
| LokelmaSodium Zirconium Cyclosilicate | 11 | $6,816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $5,623 | $277,703196 claims |
| PfizerEliquis | $182 | $130,761110 claims |
| AstraZenecaFarxiga, Lokelma | $55 | $114,292115 claims |
| Lilly USA, LLCMounjaro | $910 | $28,59328 claims |
| Johnson & JohnsonXarelto | $21 | $27,30419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Tampa
- Hiram BezerraTampa$698K
- James SmithTampa$324K
- David WilsonTampa$258K
- Robby WuTampa$190K
- Jason FelibertiTampa$138K
- Samip VasaiwalaTampa$126K
- Kevin MakatiLutz$1.6M
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.